Labiotech.eu

Interview 21 May 2020

What 2019 Can Teach About European Biotech Investments Going Forward

Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […]

May 21, 2020 - 9 minutesmins - By Jonathan Smith

News and Trends 20 May 2020

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […]

May 20, 2020 - 3 minutesmins - By Helen Albert

News and Trends 20 May 2020

Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II

MGB Biopharma has reported positive results from a phase II trial showing that its antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after. The bacterium Clostridium difficile causes life-threatening infections in the intestine and is the most common cause of diarrhea. Current treatments against it […]

May 20, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

novartis spinal muscular atrophy gene therapy

News and Trends 19 May 2020

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […]

May 19, 2020 - 5 minutesmins - By Jonathan Smith

In Depth 18 May 2020

Will Covid-19 Change the Face of Vaccine Development?

The unprecedented scale of the current Covid-19 pandemic has led to a vaccine ‘race’ the like of which has never been seen before. This may change the face of vaccine development forever. Since the English physician Edward Jenner invented the first smallpox vaccine in 1796, vaccines have resulted in dramatic reductions in deaths from previously […]

May 18, 2020 - 13 minutesmins - By Helen Albert

News and Trends 18 May 2020

Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats

Update (18/05/2020): Cubiq Foods has received a €5M investment from food technology investor Blue Horizon Ventures. With the funds, the startup aims to accelerate the production of its omega 3 fat additives based on cell culture, expecting to launch two products by the end of the year. 31/01/2019 Based in Barcelona, Cubiq Foods is developing […]

May 18, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 May 2020

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […]

May 15, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 15 May 2020

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide

Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic droplets, which could lead to the production of organic chemicals and clean fuels that is more efficient than nature can achieve alone. In a study recently published in Science, the research team developed an automated way to produce artificial versions […]

May 15, 2020 - 3 minutesmins - By David Kirk

News and Trends 15 May 2020

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […]

May 15, 2020 - 4 minutesmins - By Laura Cowen

genmab janssen blood cancer multiple myeloma

News and Trends 14 May 2020

Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market

Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations and driving the launch of its targeted chemotherapy drug in the US. In what could be one of European biotech’s largest equity boosts this year, the company exceeded initial plans to raise €111M (SEK 1.2M) through Nasdaq Stockholm following a […]

May 14, 2020 - 3 minutesmins - By Anita Chakraverty

Innovative Medicines Initiative Covid 19

News and Trends 14 May 2020

EU Initiative Pumps up Funding for Covid-19 Research to €117M

The funding will go towards eight research projects that have been selected out of 144 proposals received by the EU’s Innovative Medicines Initiative. In March, the Innovative Medicines Initiative (IMI) opened a fast-track call for proposals on diagnostics and treatments for the coronavirus outbreak. Due to the large number of high-quality proposals received, the IMI […]

May 14, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 May 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]

May 13, 2020 - 4 minutesmins - By Helen Albert

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What 2019 Can Teach About European Biotech Investments Going Forward

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Will Covid-19 Change the Face of Vaccine Development?

Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market

EU Initiative Pumps up Funding for Covid-19 Research to €117M

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!